To Evaluate the Safety and Efficacy of Sofosbuvir and Ribavirin in Patients With HCV (Genotype 3) Related Decompensated Cirrhosis

Phase

TERMINATED

Status

Enrollment

OTHER

Sponsor class

Stopped In view of recent approval of NS5A inhibitors for treatment of hepatitis C such as Declatasvir and Ledipasvir which have proven better efficacy in the HCV cure

Conditions

HCV Related Cirrhosis

Interventions

DRUG: Sofosbuvir + Ribavirin 1
DRUG: Sofosbuvir + Ribavirin 2
DRUG: Sofosbuvir + Ribavirin 3

Sponsor

Institute of Liver and Biliary Sciences, India